➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Express Scripts
Boehringer Ingelheim
Colorcon
McKinsey

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

CEFAZOLIN AND DEXTROSE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cefazolin And Dextrose patents expire, and what generic alternatives are available?

Cefazolin And Dextrose is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in CEFAZOLIN AND DEXTROSE is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Cefazolin And Dextrose

A generic version of CEFAZOLIN AND DEXTROSE was approved as cefazolin sodium by SANDOZ on December 9th, 1988.

  Start Trial

Drug patent expirations by year for CEFAZOLIN AND DEXTROSE
Recent Clinical Trials for CEFAZOLIN AND DEXTROSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Legacy Health SystemN/A
Lawson Health Research InstitutePhase 2/Phase 3
Assistance Publique - Hôpitaux de ParisPhase 3

See all CEFAZOLIN AND DEXTROSE clinical trials

Pharmacology for CEFAZOLIN AND DEXTROSE

US Patents and Regulatory Information for CEFAZOLIN AND DEXTROSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
B Braun CEFAZOLIN AND DEXTROSE cefazolin sodium INJECTABLE;INJECTION 050779-002 Jul 27, 2000 RX Yes Yes   Start Trial   Start Trial   Start Trial
B Braun CEFAZOLIN AND DEXTROSE cefazolin sodium INJECTABLE;INJECTION 050779-003 Jan 13, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
B Braun CEFAZOLIN AND DEXTROSE cefazolin sodium INJECTABLE;INJECTION 050779-001 Jul 27, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Moodys
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.